Point-Of-Care-Testing (POCT) Market Report 2026

Point-Of-Care-Testing (POCT) Market Overview

• Point-Of-Care-Testing (POCT) market size has reached to $50.79 billion in 2025 • Expected to grow to $86.91 billion in 2030 at a compound annual growth rate (CAGR) of 11.3% • Growth Driver: Increasing Adoption Of Telemedicine Fueling The Growth Of The Market Due To Rising Demand For Convenient And Contact-free Healthcare Services • Market Trend: New Point-Of-Care System Delivers Full Antimicrobial Susceptibility Results In 30 Minutes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Point-Of-Care-Testing (POCT) Market?

Point-of-care testing (POCT) refers to diagnostic testing performed at or near the site of patient care, allowing for immediate results and faster clinical decision-making. Its purpose is to provide quick and accurate diagnostic results directly at the site of patient care, enabling quicker clinical decisions, timely treatment and improved patient outcomes. The main types of point-of-care testing (POCT) include blood glucose testing, infectious disease testing, cardiac marker testing, coagulation testing, pregnancy and fertility testing, blood gas or electrolyte testing, urinalysis testing, and others. Blood glucose testing refers to the process of measuring the amount of sugar (glucose) in a person’s blood to help monitor and manage conditions. POCT products are available through different modes of purchase, such as over-the-counter products and prescription-based products, and use various technologies, including immunoassays, molecular diagnostics, microbial detection, polymerase chain reaction (PCR) testing, and biochemical testing. Key end users include clinical laboratories, ambulatory care facilities, physician offices, pharmacies, retail clinics, e-commerce platforms, hospitals, critical care centers, urgent care centers, home care and self-testing, and others.

What Is The Point-Of-Care-Testing (POCT) Market Growth Forecast?

The point-of-care-testing (poct) market size is expected to see rapid growth in the next few years. It will grow to $86.91 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to advancement in poct device miniaturization, expansion of home care and remote patient monitoring, growing infectious disease outbreaks, increasing healthcare decentralization, rising adoption of self-testing diagnostics. Major trends in the forecast period include growing adoption of rapid diagnostic testing at point of care, rising demand for home-based and self-testing solutions, expansion of over-the-counter diagnostic products, increasing focus on early disease detection and screening, improved accuracy and sensitivity of poct devices.

Global Point-Of-Care-Testing (POCT) Market Segmentation

1) By Type: Blood Glucose Testing, Infectious Diseases Testing, Cardiac Markers Testing, Coagulation Testing, Pregnancy And Fertility Testing, Blood Gas Or Electrolytes Testing, Urinalysis Testing, Other Types 2) By Mode Of Purchase: Over-The-Counter Products, Prescribed Based Products 3) By Technology: Immunoassays, Molecular Diagnostics, Microbial Detection, Polymerase Chain Reaction (PCR) Testing, Biochemical Testing 4) By End-User: Clinical Laboratories, Ambulatory Care Facilities And Physician Offices, Pharmacies, Retail Clinics And E-Comm Platforms, Hospitals, Critical Care Centres, Urgent Care Centres, Home Care And Self-Testing, Other End-Users Subsegments: 1) By Blood Glucose Testing: Self-Monitoring Blood Glucose Devices, Continuous Glucose Monitoring Devices, Flash Glucose Monitoring Devices 2) By Infectious Diseases Testing: Human Immunodeficiency Virus (HIV) Testing, Hepatitis Testing, Influenza Testing, COVID-19 Testing, Other Infectious Diseases Testing 3) By Cardiac Markers Testing: Troponin Testing, Creatine Kinase-MB (CK-MB) Testing, Myoglobin Testing, B-type Natriuretic Peptide (BNP) Testing 4) By Coagulation Testing: Prothrombin Time (PT) Testing, Activated Partial Thromboplastin Time (aPTT) Testing, International Normalized Ratio (INR) Testing 5) By Pregnancy And Fertility Testing: Pregnancy Test Kits, Ovulation Test Kits, Fertility Hormone Testing 6) By Blood Gas Or Electrolytes Testing: Arterial Blood Gas Testing, Venous Blood Gas Testing, Electrolyte Testing 7) By Urinalysis Testing: Urine Chemistry Analysis, Microscopic Urine Analysis, Urine Culture Testing 8) By Other Types: Drug Abuse Testing, Allergy Testing, Cholesterol Testing, Thyroid Function Testing

What Is The Driver Of The Point-Of-Care-Testing (POCT) Market?

The increasing adoption of telemedicine is expected to propel the growth of the point-of-care-testing (POCT) market going forward. Telemedicine refers to the practice of delivering medical care remotely, using digital communication technologies such as video calls, phone calls, or secure messaging. The adoption of telemedicine is due to rising demand for convenient, timely, and contact-free healthcare services, particularly accelerated by the COVID-19 pandemic. Point-of-care testing (POCT) supports telemedicine by providing rapid, reliable diagnostic results that can be shared instantly with remote healthcare providers. For instance, in April 2025, according to the American Hospital Association, a US-based professional organization company, in 2023, more than 12.6% of Medicare beneficiaries utilized telehealth services. By 2036, the number of physicians is projected to reach up to 86,000. Telehealth plays a vital role in helping to mitigate the increasing physician shortage. Therefore, the increasing adoption of telemedicine is driving the growth of the point-of-care-testing (POCT) industry.

Key Players In The Global Point-Of-Care-Testing (POCT) Market

Major companies operating in the point-of-care-testing (poct) market are Johnson & Johnson, F. Hoffmann‑La Roche Ltd., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company, BioMérieux SA, QuidelOrtho Corporation, Sysmex Corporation, Nova Biomedical Corporation, LifeScan Inc., Ascensia Diabetes Care Holdings AG, Trividia Health Inc., Trinity Biotech Plc, Sinocare Inc., Menarini Diagnostics, Princeton BioMeditech, Helena Laboratories, Chembio Diagnostics, ARKRAY, Accriva, ACON Laboratories, Sekisui Diagnostics, PTS Diagnostics, Meridian Bioscience

Global Point-Of-Care-Testing (POCT) Market Trends and Insights

Major companies in the point-of-care testing (POCT) market are increasingly focusing on technological innovations, such as microfluidic rapid antimicrobial-susceptibility testing (AST) systems, to address the growing need for faster, clinic-level diagnostics and improved antimicrobial stewardship in primary care. This microfluidic AST technology leverages fluid channels at the micrometer scale to culture and detect bacteria from patient samples—such as urine—and determine their antibiotic susceptibility in a fraction of the time required by conventional culture-based methods, which can take several days. For example, in June 2023, Sysmex Corporation, a Japan-based diagnostics company, introduced the PA 100 AST System, a compact POCT analyser that employs Sysmex Astrego’s proprietary microfluidic cartridges to detect bacteria in approximately 15 minutes and provide complete AST results in about 30 minutes. The system is highly user-friendly: healthcare professionals simply place the sample into a single-use cartridge, insert it into the desktop analyser, and receive automated AST readouts without needing specialized laboratory training. This rapid turnaround allows timely antibiotic decisions during the first patient visit, supporting efforts to reduce inappropriate prescriptions and combat antimicrobial resistance (AMR).

What Are Latest Mergers And Acquisitions In The Point-Of-Care-Testing (POCT) Market?

In August 2024, Quest Diagnostics Inc., a US-based medical laboratory company, acquired LifeLabs LP for $1 billion (CAN $1.35 billion). Through this acquisition, Quest Diagnostics aims to expand its diagnostic services and enhance access to innovative healthcare solutions. LifeLabs LP is a Canada-based provider of point of care testing (POCT) services.

Regional Outlook

North America was the largest region in the point-of-care testing (POCT) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Point-Of-Care-Testing (POCT) Market?

The point-of-care testing (POCT) market includes revenues earned by entities by providing services such as on-site diagnostic testing, rapid disease detection, mobile health screening, and patient self-testing support. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care testing (POCT) market includes sales of portable HbA1c analyzers, handheld blood gas analyzers, CRP (C-reactive protein) test kits, multiplex respiratory pathogen detection kits, and lateral flow urine analysis devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.